176 related articles for article (PubMed ID: 32114746)
1. [Drug interaction monitoring of lopinavir/ritonavir in COVID-19 patients with cancer].
Zheng XW; Tao G; Zhang YW; Yang GN; Huang P
Zhonghua Nei Ke Za Zhi; 2020 May; 59(5):400-404. PubMed ID: 32114746
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 & antiepileptic drugs: Should we pay attention?
Fırat O; Yalçın N; Demirkan K
Seizure; 2020 Aug; 80():240-241. PubMed ID: 32663783
[No Abstract] [Full Text] [Related]
3. The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Habibzadeh P; Moghadami M; Lankarani KB
Med Hypotheses; 2020 Oct; 143():109847. PubMed ID: 32460209
[No Abstract] [Full Text] [Related]
4. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.
Beyls C; Martin N; Hermida A; Abou-Arab O; Mahjoub Y
Circ Arrhythm Electrophysiol; 2020 Aug; 13(8):e008798. PubMed ID: 32809882
[No Abstract] [Full Text] [Related]
6. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
[TBL] [Abstract][Full Text] [Related]
7. Ritonavir/Lopinavir and Its Potential Interactions With Psychiatric Medications: A COVID-19 Perspective.
Mansuri Z; Shah B; Adnan M; Chaudhari G; Jolly T
Prim Care Companion CNS Disord; 2020 Jun; 22(3):. PubMed ID: 32569450
[No Abstract] [Full Text] [Related]
8. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
Stalder G; Alberio L
Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
[No Abstract] [Full Text] [Related]
9. Treating COVID-19 with Chloroquine.
Huang M; Tang T; Pang P; Li M; Ma R; Lu J; Shu J; You Y; Chen B; Liang J; Hong Z; Chen H; Kong L; Qin D; Pei D; Xia J; Jiang S; Shan H
J Mol Cell Biol; 2020 May; 12(4):322-325. PubMed ID: 32236562
[No Abstract] [Full Text] [Related]
10. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
11. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19.
Zhu Z; Lu Z; Xu T; Chen C; Yang G; Zha T; Lu J; Xue Y
J Infect; 2020 Jul; 81(1):e21-e23. PubMed ID: 32283143
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
13. Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Gougis P; Fenioux C; Funck-Brentano C; Veyri M; Gligorov J; Solas C; Spano JP
Eur J Cancer; 2020 Sep; 136():1-3. PubMed ID: 32610172
[TBL] [Abstract][Full Text] [Related]
14. BET 1: Lopinavir-ritonavir and COVID-19.
Dolan D; Ingham J; Baombe J
Emerg Med J; 2020 Jul; 37(7):450-451. PubMed ID: 32616658
[No Abstract] [Full Text] [Related]
15. [Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19].
Vecchio G; Zapico V; Catanzariti A; Carboni Bisso I; Las Heras M
Medicina (B Aires); 2020; 80(5):439-441. PubMed ID: 33048786
[TBL] [Abstract][Full Text] [Related]
16. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Bartiromo M; Borchi B; Botta A; Bagalà A; Lugli G; Tilli M; Cavallo A; Xhaferi B; Cutruzzulà R; Vaglio A; Bresci S; Larti A; Bartoloni A; Cirami C
Transpl Infect Dis; 2020 Aug; 22(4):e13286. PubMed ID: 32279418
[TBL] [Abstract][Full Text] [Related]
17. Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
Owa AB; Owa OT
J Microbiol Immunol Infect; 2020 Oct; 53(5):674-675. PubMed ID: 32474026
[TBL] [Abstract][Full Text] [Related]
18. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
Schoergenhofer C; Jilma B; Stimpfl T; Karolyi M; Zoufaly A
Ann Intern Med; 2020 Oct; 173(8):670-672. PubMed ID: 32422065
[No Abstract] [Full Text] [Related]
20. Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Baralić K; Jorgovanović D; Živančević K; Antonijević Miljaković E; Antonijević B; Buha Djordjevic A; Ćurčić M; Đukić-Ćosić D
Toxicol Appl Pharmacol; 2020 Nov; 406():115237. PubMed ID: 32920000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
